
Gateway Genomics
Gateway Genomics is a personal genomics company whose SneakPeek brand gives parents prenatal and newborn information.

Gateway Genomics is a personal genomics company whose SneakPeek brand gives parents prenatal and newborn information.
sneakpeektest.comCrawled Nov 21, 2026
The company’s privacy policy explains how it collects, uses, and protects user information.
Myriad Genetics sells its Prenatal Health testing division to Labcorp in a cash deal. The transaction values the business at $210 million. Labcorp expands its genetic testing portfolio with the acquisition.
Myriad Genetics sells its prenatal testing division to Labcorp in a $210 million deal. The transaction refocuses Myriad’s business strategy by divesting the prenatal testing segment. Labcorp expands its diagnostic testing capabilities through the acquisition.
Labcorp has acquired Myriad Genetics’ prenatal testing division, including the Prequel®, Foresight®, SneakPeek®, and FirstGene® tests, for $210 million in cash. The deal expands Labcorp’s prenatal health diagnostics portfolio, leveraging Myriad’s established molecular testing expertise. Myriad retains its broader precision medicine and molecular diagnostics operations outside prenatal care.
Myriad Genetics acquires Gateway Genomics, a developer of consumer-focused prenatal and pediatric genomic tests, for $67.5 million in cash. The deal includes potential additional payments of up to $32.5 million in 2023 and 2024, contingent on meeting revenue, volume, and EBITDA targets. Gateway Genomics specializes in genomic testing solutions for families.
Myriad Genetics reports a **7% revenue decline** to **$156.4 million** in Q3, missing estimates, while acquiring **Gateway Genomics** and its **SneakPeek Early Gender DNA Test**. The acquisition expands Myriad’s prenatal and consumer genetics portfolio. The company cites ongoing market challenges in its core hereditary cancer testing segment.
Myriad Genetics acquires Gateway Genomics, gaining access to its SneakPeek Early Gender DNA test, a leading product in the consumer genetic testing market. The move aims to broaden Myriad’s reach in at-home genetic testing solutions. Gateway Genomics holds a prominent position with its early gender DNA test, catering to expectant parents seeking prenatal insights.
Myriad Genetics Inc has acquired Gateway Genomics LLC in a deal valued at around **$110 million**. The transaction expands Myriad’s genomic testing capabilities, though specific terms beyond the purchase price remain undisclosed. The company integrates Gateway’s technology into its existing portfolio, potentially strengthening its position in precision medicine and genetic diagnostics.